AR027902A1 - Preparacion medicamentosa plana para la administracion transmucosa de oxicodona o un principio activo similar en la cavidad bucal, para su aplicacion en el tratamiento contra el dolor y la adiccion - Google Patents

Preparacion medicamentosa plana para la administracion transmucosa de oxicodona o un principio activo similar en la cavidad bucal, para su aplicacion en el tratamiento contra el dolor y la adiccion

Info

Publication number
AR027902A1
AR027902A1 ARP000106618A ARP000106618A AR027902A1 AR 027902 A1 AR027902 A1 AR 027902A1 AR P000106618 A ARP000106618 A AR P000106618A AR P000106618 A ARP000106618 A AR P000106618A AR 027902 A1 AR027902 A1 AR 027902A1
Authority
AR
Argentina
Prior art keywords
oxicodone
addiction
medicinal
application
oral cavity
Prior art date
Application number
ARP000106618A
Other languages
English (en)
Original Assignee
Lohmann Therapie Syst Lts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lohmann Therapie Syst Lts filed Critical Lohmann Therapie Syst Lts
Publication of AR027902A1 publication Critical patent/AR027902A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ARP000106618A 1999-12-14 2000-12-13 Preparacion medicamentosa plana para la administracion transmucosa de oxicodona o un principio activo similar en la cavidad bucal, para su aplicacion en el tratamiento contra el dolor y la adiccion AR027902A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19960154A DE19960154A1 (de) 1999-12-14 1999-12-14 Flache Arzneizubereitung zur transmucosalen Verabreichung von Oxycodon oder einem vergleichbaren Wirkstoff in der Mundhöhle, für die Anwendung in der Schmerztherapie und Suchttherapie

Publications (1)

Publication Number Publication Date
AR027902A1 true AR027902A1 (es) 2003-04-16

Family

ID=7932547

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000106618A AR027902A1 (es) 1999-12-14 2000-12-13 Preparacion medicamentosa plana para la administracion transmucosa de oxicodona o un principio activo similar en la cavidad bucal, para su aplicacion en el tratamiento contra el dolor y la adiccion

Country Status (18)

Country Link
US (1) US20040024003A1 (es)
EP (1) EP1239847A1 (es)
JP (1) JP2003516961A (es)
KR (1) KR100597806B1 (es)
CN (1) CN1407889A (es)
AR (1) AR027902A1 (es)
AU (1) AU781946B2 (es)
BR (1) BR0016504A (es)
CA (1) CA2393838A1 (es)
CZ (1) CZ20022063A3 (es)
DE (1) DE19960154A1 (es)
HU (1) HUP0203733A2 (es)
IL (1) IL150127A0 (es)
MX (1) MXPA02005857A (es)
PL (1) PL355816A1 (es)
RU (1) RU2002115277A (es)
WO (1) WO2001043728A1 (es)
ZA (1) ZA200204225B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
WO2003099263A1 (de) * 2002-05-24 2003-12-04 Agfa-Gevaert Wirkstoff enthaltende, zumindest teilweise abbaubare folien und verfahren zuderen herstellung
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
AU2004319243B2 (en) * 2003-05-28 2010-06-03 Aquestive Therapeutics, Inc. Polyethylene oxide-based films and drug delivery systems made therefrom
DE10332160A1 (de) * 2003-07-15 2005-02-03 Röhm GmbH & Co. KG Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Peptid- oder Protein-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform
US8003122B2 (en) * 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US7846940B2 (en) * 2004-03-31 2010-12-07 Cordis Corporation Solution formulations of sirolimus and its analogs for CAD treatment
DE102005007859A1 (de) * 2005-02-21 2006-08-24 Lts Lohmann Therapie-Systeme Ag Vefahren für eine medikamentöse Kombinations-Behandlung, sowie hierfür geeignete Arzneimittel-Kombinationen
CN1813740B (zh) * 2005-11-22 2010-05-05 岳振江 一种含有盐酸纳洛酮的舌下膜剂及其制备方法
WO2007070632A2 (en) * 2005-12-13 2007-06-21 Biodelivery Sciences International, Inc. Abuse resistant transmucosal drug delivery device
DE102006027792A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Antidepressiva-Kombinations-Wafer
DE102006027794A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Antihypertonie-Kombinationswafer
DE102006027793A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Opioid-Kombinations-Wafer
DE102006027791A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag AchE-NMDA-Kombinationswafer
DE102006027790A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Typ-2-Diabetes Kombinations-Wafer
AU2007275581B2 (en) * 2006-07-21 2011-09-08 Biodelivery Sciences International, Inc. Transmucosal delivery devices with enhanced uptake
US8420110B2 (en) * 2008-03-31 2013-04-16 Cordis Corporation Drug coated expandable devices
AU2009271271A1 (en) * 2008-06-23 2010-01-21 Biodelivery Sciences International, Inc. Multidirectional mucosal delivery devices and methods of use
US20110269841A1 (en) * 2010-05-03 2011-11-03 Innoteq, Inc. Thin film with methadone active ingredient
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
WO2013026064A1 (en) 2011-08-18 2013-02-21 Biodelivery Sciences International, Inc. Abuse-resistant mucoadhesive devices for delivery of buprenorphine
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
KR20190110628A (ko) * 2011-12-21 2019-09-30 바이오딜리버리 사이언시스 인터내셔널 인코포레이티드 만성 통증 완화에 이용되는 점막 관통 약물 전달 장치
WO2013171146A1 (en) * 2012-05-15 2013-11-21 Lts Lohmann Therapie-Systeme Ag Oral film containing enteric release opiate resinate
JP7653218B2 (ja) 2016-05-05 2025-03-28 アクエスティブ セラピューティクス インコーポレイテッド 送達増強エピネフリン組成物
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
IL318587A (en) * 2018-07-23 2025-03-01 Trevi Therapeutics Inc Treatment of chronic cough, shortness of breath and wheezing
CA3166928A1 (en) 2020-01-10 2021-07-15 Trevi Therapeutics, Inc. Methods of administering nalbuphine
US12465564B2 (en) 2021-10-25 2025-11-11 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626539A (en) * 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
JPH02503672A (ja) * 1987-06-01 1990-11-01 ワーナー‐ランバート・コンパニー 水性の系における浸透促進剤としての脂肪酸およびその短鎖エステル
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
DE19642043A1 (de) * 1995-10-23 1997-04-24 Hexal Ag Transdermales therapeutisches System (TTS) für die Verabreichung von Wirkstoffen zur Behandlung von Drogenabhängigkeit oder Drogensucht
DE19652188C2 (de) * 1996-12-16 2002-02-14 Lohmann Therapie Syst Lts Flache Arzneizubereitung zur Applikation und Freisetzung von Buprenorphin oder einer pharmakologisch vergleichbaren Substanz in der Mundhöhle und Verfahren zu ihrer Herstellung
ES2252865T3 (es) * 1997-09-26 2006-05-16 Noven Pharmaceuticals, Inc. Composiciones bioadhesivas y metodos para la administracion topica de agentes activos.
DE19923551A1 (de) * 1999-05-21 2000-11-30 Lohmann Therapie Syst Lts Pharmazeutisches Präparat mit dem Wirkstoff Diamorphin und seine Verwendung in einem Verfahren zur Behandlung der Opiatsucht

Also Published As

Publication number Publication date
WO2001043728A1 (de) 2001-06-21
JP2003516961A (ja) 2003-05-20
US20040024003A1 (en) 2004-02-05
BR0016504A (pt) 2002-11-05
AU781946B2 (en) 2005-06-23
CZ20022063A3 (cs) 2002-09-11
MXPA02005857A (es) 2002-10-23
EP1239847A1 (de) 2002-09-18
ZA200204225B (en) 2003-03-03
AU2839201A (en) 2001-06-25
KR20020067544A (ko) 2002-08-22
HUP0203733A2 (en) 2003-05-28
DE19960154A1 (de) 2001-07-12
CN1407889A (zh) 2003-04-02
RU2002115277A (ru) 2004-01-10
CA2393838A1 (en) 2001-06-21
KR100597806B1 (ko) 2006-07-10
PL355816A1 (en) 2004-05-17
IL150127A0 (en) 2002-12-01

Similar Documents

Publication Publication Date Title
IL150127A0 (en) Flat medicinal preparation for transmucosal administration of oxycodon or a comparable active ingredient in the oral cavity, for use in pain therapy and in addiction therapy
MXPA02012793A (es) Composicion de dilatacion rapida para la retencion gastrica y la liberacion controlada de agentes terapeuticos y formas de dosificacion de la composicion.
PL334656A1 (en) Dosage forms and methods of achieving betterement in cases of erection disorderamong male patients
EP1242013A4 (en) ORAL TRANSMUCOSAL GALENIC FORM USING SOLID SOLUTION
HUP0302319A3 (en) Pharmaceutical composition for oral administration of active ingredient
ZA200300316B (en) Rapidly decomposing administrable form for releasing active ingredient in the oral cavity or in body cavities.
ES2180646T3 (es) Formulaciones liquidas orales de alendronato.
ATE429213T1 (de) Mucoadhäsive zerfallsfähige arzneizubereitung zur wirkstoffverabreichung in der veterinär- und humanmedicin
NZ520015A (en) Hydroxide-releasing agents as skin permeation enhancers
MX2007015480A (es) Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada.
GB2368525B (en) Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
IL155097A0 (en) Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
ATE262893T1 (de) Darreichungsformen zur behandlung von oralen mykosen
MY144781A (en) Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity
EP1583545A4 (en) PHARMACEUTICAL COMPOSITION FOR IMPROVED ADMINISTRATION OF PEPTIDES OF HIV GP41 AND ITS THERAPEUTIC USE
NO20055601D0 (no) Farmasoytisk preparat i form av en hydrogel for transdermal administrasjon av aktive virkestoffer
GB0500594D0 (en) Oral delivery of biological active agents in a nanoemulsion formulation to the human body
JP2001316293A5 (es)
IL161114A (en) Use of specific dose of fondaparinux sodium in the preparation of a medicament for the treatment of acs
IL155855A0 (en) Pharmaceutical formulation of gepirone for oral administration
John et al. Locally delivered antimicrobials in periodontal treatment
Yun et al. Pharmaceutical devices for oral cavity-based local and systemic drug delivery
HU0500745D0 (en) Rapidly decomposable pharmaceutical dosage form for use in oral or body cavity containing nicotine as active ingredient
MXPA02007641A (es) Uso de farmaceutico de la combinacion de fluconazol-tinidazol y su composicion para la administracion oral.
AR024199A1 (es) Uso de la buprenorfina en la preparacion de un disposotivo de suministro transdermico

Legal Events

Date Code Title Description
FB Suspension of granting procedure